Raloxifene
Alternative Names: Celvista; Evista; Keoxifene; LY 139481; LY 156758; Optruma; Sevista (raloxifene)Latest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Calcium regulators; Osteoporosis therapies; Small molecules; Stilbenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Fracture; Postmenopausal osteoporosis
- No development reported Cardiovascular disorders; Endometriosis; Hypercholesterolaemia; Leiomyoma; Vasomotor symptoms